Kirk J. Rowley

Kirk J. Rowley

Auto-generated profile, based on publicly available information

Kirk J. Rowley

MassBiologics, University of Massachusetts Medical School, Boston, Massachusetts, United States of America

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 August 2012 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
TMTrevor J. Morin
Trevor J. Morin
TBTeresa J. Broering
Teresa J. Broering
BLBrett A. Leav
Brett A. Leav
BBBarbra M. Blair
Barbra M. Blair
KRKirk J. Rowley
Kirk J. Rowley
GBGregory J. Babcock
Gregory J. Babcock
Hepatitis C virus (HCV) infection is a leading cause of liver transplantation and there is an urgent need to develop therapies to reduce rates of HCV infection of transplanted livers. Approved therapeutics for HCV are poorly tolerated and are of limited efficacy in this patient population. Human monoclonal antibody HCV1 recognizes a highly-conserved linear epitope of the HCV E2 envelope glycoprotein (amino acids 412–423) and neutralizes a broad range of HCV genotypes. In a chimpanzee model, a single dose of 250 mg/kg HCV1 delivered 30 minutes prior to infusion with genotype 1a H77 HCV provided complete protection from HCV infection, whereas a dose of 50 mg/kg HCV1 did not protect. In addition, an acutely-infected chimpanzee given 250 mg/kg HCV1 42 days following exposure to virus had a rapid reduction in viral load to below the limit of detection before rebounding 14 days later. The emergent virus displayed an E2 mutation (N415K/D) conferring resistance to HCV1 neutralization. Finally, three chronically HCV-infected chimpanzees were treated with a single dose of 40 mg/kg HCV1 and viral load was reduced to below the limit of detection for 21 days in one chimpanzee with rebounding virus displaying a resistance mutation (N417S). The other two chimpanzees had 0.5–1.0 log10 reductions in viral load without evidence of viral resistance to HCV1. In vitro testing using HCV pseudovirus (HCVpp) demonstrated that the sera from the poorly-responding chimpanzees inhibited the ability of HCV1 to neutralize HCVpp. Measurement of antibody responses in the chronically-infected chimpanzees implicated endogenous antibody to E2 and interference with HCV1 neutralization although other factors may also be responsible. These data suggest that human monoclonal antibody HCV1 may be an effective therapeutic for the prevention of graft infection in HCV-infected patients undergoing liver transplantation. The majority of individuals infected with hepatitis C virus (HCV) become chronically infected and many go on to develop liver failure requiring liver transplantation. Unfortunately, the transplanted liver becomes infected with HCV in nearly 100% of transplant patients. Current treatments for HCV are poorly tolerated after liver transplantation and graft health is compromised by infection. We have developed a monoclonal antibody called HCV1 that blocks HCV from infecting liver cells in culture. Using chimpanzees as a model for HCV infection, we demonstrate that HCV1 has the ability to prevent HCV infection. We also show that HCV1 can treat chimpanzees chronically infected with HCV and reduce plasma viral load to below the level of detection for a period of 7 to 21 days. The virus that reemerges in the treated chimpanzees was resistant to HCV1 neutralization demonstrating target engagement. Given the ability of HCV1 to protect chimpanzees from HCV infection, we speculate that HCV1 may be beneficial in HCV- infected patients undergoing liver transplant.

1 July 2015 in Cell
Verified
Journal Article
Closed access
LRLuke N. Robinson
Luke N. Robinson
KTKannan Tharakaraman
Kannan Tharakaraman
KRKirk J. Rowley
Kirk J. Rowley
VCVivian V. Costa
Vivian V. Costa
KCKuan Rong Chan
Kuan Rong Chan
RSRam Sasisekharan
Ram Sasisekharan

1 April 2007 in Vaccine
Verified
Journal Article
Closed access
SSSusan E. Sloan
Susan E. Sloan
CHCathleen Hanlon
Cathleen Hanlon
WWWilliam Weldon
William Weldon
MNMichael Niezgoda
Michael Niezgoda
JBJesse Blanton
Jesse Blanton
DADonna M. Ambrosino
Donna M. Ambrosino

1 November 2013 in Infection and Immunity
Verified
Journal Article
Closed access
PDF file
LSLeila M. Sevigny
Leila M. Sevigny
BBBrian J. Booth
Brian J. Booth
KRKirk J. Rowley
Kirk J. Rowley
BLBrett A. Leav
Brett A. Leav
PCPeter S. Cheslock
Peter S. Cheslock
YWYang Wang
Yang Wang
Diphtheria antitoxin (DAT) has been the cornerstone of the treatment of Corynebacterium diphtheriae infection for more than 100 years. Although the global incidence of diphtheria has declined steadily over the last quarter of the 20th century, the disease remains endemic in many parts of the world, and significant outbreaks still occur. DAT is an equine polyclonal antibody that is not commercially available in the United States and is in short supply globally. A safer, more readily available alternative to DAT would be desirable. In the current study, we obtained human monoclonal antibodies (hMAbs) directly from antibody-secreting cells in the circulation of immunized human volunteers. We isolated a panel of diverse hMAbs that recognized diphtheria toxoid, as well as a variety of recombinant protein fragments of diphtheria toxin. Forty-five unique hMAbs were tested for neutralization of diphtheria toxin in in vitro cytotoxicity assays with a 50% effective concentration of 0.65 ng/ml for the lead candidate hMAb, 315C4. In addition, 25 μg of 315C4 completely protected guinea pigs from intoxication in an in vivo lethality model, yielding an estimated relative potency of 64 IU/mg. In comparison, 1.6 IU of DAT was necessary for full protection from morbidity and mortality in this model. We further established that our lead candidate hMAb binds to the receptor-binding domain of diphtheria toxin and physically blocks the toxin from binding to the putative receptor, heparin-binding epidermal growth factor-like growth factor. The discovery of a specific and potent human neutralizing antibody against diphtheria toxin holds promise as a potential therapeutic.

31 August 2011 in Antiviral Research
Verified
Journal Article
Closed access
YWYang Wang
Yang Wang
KRKirk J. Rowley
Kirk J. Rowley
BBBrian J. Booth
Brian J. Booth
SSSusan E. Sloan
Susan E. Sloan
DADonna M. Ambrosino
Donna M. Ambrosino
GBGregory J. Babcock
Gregory J. Babcock

1 August 2017 in Antiviral Research
Verified
Journal Article
Open access
EZEugenia Ong Ziying
Eugenia Ong Ziying
YBYadunanda Budigi
Yadunanda Budigi
HTHwee Cheng Tan
Hwee Cheng Tan
LRLuke N. Robinson
Luke N. Robinson
KRKirk J. Rowley
Kirk J. Rowley
EOEng Eong Ooi
Eng Eong Ooi
Despite useful in vivo activity, no therapeutic against dengue virus (DENV) has demonstrated efficacy in clinical trials. Herein, we explored dosing and virological endpoints to guide the design of human trials of VIS513, a pan-serotype anti-DENV IgG1 antibody, in non-human primates (NHPs). Dosing VIS513 pre- or post-peak viremia in NHPs neutralized infectious DENV although RNAemia remained detectable post-treatment; differential interaction of human IgGs with macaque Fc-gamma receptors may delay clearance of neutralized DENV. Our findings suggest useful antiviral utility of VIS513 and highlight an important consideration when evaluating virological endpoints of trials for anti-DENV biologics.